Advertisement

Topics

Pharnext to Showcase Pioneering PLEOTHERAPY™ R&D Platform at 6th Annual Drug Repositioning, Repurposing and Rescue Conference

11:45 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known ...

Other Sources for this Article

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
VP, Chief Commercial Officer
contact@pharnext.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol / Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
sarah@sternir.com
or
Media Relations (U.S.)
Russo Partners
Tony Russo, +1 212-845-4251
Scott Santiamo, +1 718-344-5843
tony.russo@russopartnersllc.com
scott.santiamo@russopartnersllc.com
or
Financial Communication (France)
NewCap
Emmanuel Huyn, +33 (0)1 44 71 20 40
pharnext@newcap.eu

NEXT ARTICLE

More From BioPortfolio on "Pharnext to Showcase Pioneering PLEOTHERAPY™ R&D Platform at 6th Annual Drug Repositioning, Repurposing and Rescue Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...